Sign in

Fatty liver disease (MASLD/MASH): trials that stopped early

Trials on Fatty liver disease (MASLD/MASH) that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

30 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

    Reason given in the registry

    “Study has been terminated due to poor recruitment and early evidence of futility”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.

    Ended
    Jun 2026
    Run by
    University of Minnesota
    Registry record
    NCT03587831
  2. Suspended

    NAFLD in Adolescents and Young Adults With PCOS

    Reason given in the registry

    “Lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.

    Run by
    Columbia University
    Registry record
    NCT02506946
  3. Terminated

    Non-alcoholic Steatohepatitis Registry Platform Study

    Reason given in the registry

    “Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2026.

    Ended
    Oct 2025
    Run by
    AstraZeneca
    Registry record
    NCT06123858
  4. Withdrawn

    GLP-1 RA on Liver OMICS in MASLD

    Reason given in the registry

    “no grant approved”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jul 2026.

    Ended
    Jul 2026
    Run by
    Medical College of Wisconsin
    Registry record
    NCT06982378
  5. Withdrawn

    Assessment of Fatty Liver With Thermo-acoustic Device

    Reason given in the registry

    “The sponsor withdrew from the study”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.

    Ended
    Jul 2026
    Run by
    Medical College of Wisconsin
    Registry record
    NCT04302051
  6. Terminated

    Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

    Reason given in the registry

    “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Jun 2026.

    Ended
    Apr 2025
    Phase
    Phase 2/3
    Run by
    Galectin Therapeutics Inc.
    Registry record
    NCT04365868
  7. Terminated

    Prevention of NAFLD in Hispanic Children

    Reason given in the registry

    “Study was terminated due to a lack of funding. Data collection was completed for 12-month outcomes; however, funding limitations prevented follow-up for longer timeframes, and some outcomes were not fully collected.”

    Quoted unchanged from ClinicalTrials.gov; record updated 2 Jun 2026.

    Ended
    Mar 2026
    Run by
    Emory University
    Registry record
    NCT05292352
  8. Terminated

    Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)

    Reason given in the registry

    “Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.

    Ended
    Mar 2026
    Phase
    Phase 2
    Run by
    Enyo Pharma
    Registry record
    NCT06939816
  9. Terminated

    A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)

    Reason given in the registry

    “Participants were not dosed in Part B as per the protocol.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Apr 2026.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    Eli Lilly and Company
    Registry record
    NCT06007651
  10. Withdrawn

    FCI Effectiveness in NAFLD Stratification

    Reason given in the registry

    “Funding period ended.”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2026.

    Ended
    Mar 2026
    Run by
    NHS Grampian
    Registry record
    NCT05827432
  11. Withdrawn

    Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

    Reason given in the registry

    “The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Feb 2026.

    Ended
    Nov 2025
    Run by
    University of California, San Diego
    Registry record
    NCT07255781
  12. Suspended

    A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

    Reason given in the registry

    “Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Feb 2026.

    Phase
    Phase 3
    Run by
    Galmed Research and Development, Ltd.
    Registry record
    NCT04104321
  13. Suspended

    Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

    Reason given in the registry

    “Suspended for analysis and to consider further enrollment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Jan 2026.

    Run by
    University of Pittsburgh
    Registry record
    NCT04306939
  14. Terminated

    Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

    Reason given in the registry

    “Sponsor Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Dec 2025.

    Ended
    Oct 2024
    Phase
    Phase 2
    Run by
    Zydus Therapeutics Inc.
    Registry record
    NCT03617263
  15. Terminated

    A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

    Reason given in the registry

    “Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2025.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    Takeda
    Registry record
    NCT07052682
  16. Withdrawn

    Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD

    Reason given in the registry

    “Principal investigator left the institution and study was never funded”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Jul 2025.

    Run by
    Milton S. Hershey Medical Center
    Registry record
    NCT06352177
  17. Terminated

    A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

    Reason given in the registry

    “AstraZeneca have decided to not move forward with the development of the compound.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Jul 2025.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    AstraZeneca
    Registry record
    NCT05864391
  18. Withdrawn

    Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

    Reason given in the registry

    “Institutional and funding constrains”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.

    Ended
    Dec 2024
    Phase
    Phase 1/2
    Run by
    Sadat City University
    Registry record
    NCT04761848
  19. Withdrawn

    A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.

    Phase
    Phase 3
    Run by
    Sagimet Biosciences Inc.
    Registry record
    NCT06594523
  20. Withdrawn

    A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

    Reason given in the registry

    “Business decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.

    Phase
    Phase 3
    Run by
    Sagimet Biosciences Inc.
    Registry record
    NCT06692283
  21. Withdrawn

    Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

    Reason given in the registry

    “This study has been cancelled due to business reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Sept 2024.

    Ended
    Jan 2025
    Phase
    Phase 2
    Run by
    Gannex Pharma Co., Ltd.
    Registry record
    NCT05118360
  22. Terminated

    Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

    Reason given in the registry

    “Trial terminated because of lack of efficacy in the short term acute phase.”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Sept 2024.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    Bristol-Myers Squibb
    Registry record
    NCT04267393
  23. Withdrawn

    Dexamethasone/Pancreatic Clamp P&F

    Reason given in the registry

    “Investigators' scientific priorities shifted.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2024.

    Ended
    Mar 2026
    Phase
    Phase 1
    Run by
    Columbia University
    Registry record
    NCT06126354
  24. Withdrawn

    A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

    Reason given in the registry

    “The study was withdrawn because BioMarin decided to end the overall development program. The study withdrawal was not due to any patient safety concerns.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2024.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    BioMarin Pharmaceutical
    Registry record
    NCT06138327
  25. Terminated

    A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

    Reason given in the registry

    “Study ALN-HSD-001 was terminated due to business reasons and changes in the development strategy of the product. No safety issues were found.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 May 2024.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Alnylam Pharmaceuticals
    Registry record
    NCT04565717
  26. Withdrawn

    A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease

    Reason given in the registry

    “lack of funds”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2024.

    Ended
    Dec 2024
    Phase
    Phase 2
    Run by
    The University of Texas Health Science Center, Houston
    Registry record
    NCT04371653
  27. Terminated

    Systems Biology of Gastrointestinal and Related Diseases

    Reason given in the registry

    “Lack of enrollment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 15 Dec 2023.

    Ended
    Nov 2023
    Run by
    Viome
    Registry record
    NCT05579444
  28. Terminated

    Utilization of MAsS in Patients Undergoing LT for HCC

    Reason given in the registry

    “Discontinued by Amra Medical due to funding.”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Dec 2023.

    Ended
    Nov 2023
    Run by
    Columbia University
    Registry record
    NCT05184283
  29. Withdrawn

    Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease

    Reason given in the registry

    “The study is being withdrawn due to difficulties enrolling participants and the loss of the study coordinator”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Feb 2023.

    Ended
    Dec 2023
    Run by
    Virginia Commonwealth University
    Registry record
    NCT05130346
  30. Suspended

    A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

    Reason given in the registry

    “This study was terminated due to expired drug with possibility of re-starting in the future.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2021.

    Phase
    Phase 2
    Run by
    University of California, San Diego
    Registry record
    NCT00546455

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.